Table 1 Patients' characteristics
Patient | Baseline evaluation | After treatment | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ER, % | PgR, % | HER2, % (score) | First assessment | Time A | Chemotherapy | Time B | Second assessment | ER, % | PgR, % | HER2, % (score) | HT | Clinical response | |
1 | 0 | 0 | 80 (3+) | Skin | 20 | Paclitaxel | 9 | Skin | 10 | 0 | 70 (3+) | No | PR |
2 | 0 | 0 | 70 (3+) | Pleura | 87 | Paclitaxel | 11 | Pleura | 0 | 0 | 75 (3+) | No | SD |
3 | 0 | 0 | 90 (3+) | Skin | 8 | Nonea | 4 | Skin | 0 | 0 | 90 (3+) | No | PR |
4 | 0 | 0 | 40 (3+) | Skin | 31 | Paclitaxel | 9 | Skin | 0 | 0 | 90 (3+) | No | PD |
5 | 0 | 0 | 90 (3+) | Liver | 5 | Nonea | 12 | Ovary | 50 | 40 | 80 (3+) | Yes | PD |
6 | 0 | 0 | 95 (3+) | Breast | 2 | Paclitaxel | 37 | Breast | 20 | 0 | 90 (3+) | Yes | PR |
7 | 0 | 0 | 80 (3+) | Skin | 64 | Nonea | 4 | Skin | 0 | 0 | 95 (3+) | No | PR |
8 | 0 | 0 | 90 (3+) | Lung | 2 | Paclitaxel | 4 | Skin | 0 | 0 | 90 (3+) | No | SD |
9 | 0 | 0 | 80 (3+) | Skin | 51 | Paclitaxel | 22 | Skin | 0 | 0 | 40 (2+) | No | PR |
10 | 0 | 0 | 90 (3+) | Skin | 17 | Vinorelbine | 3 | Skin | 0 | 0 | 90 (3+) | No | PR |